Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 27, Issue 1, 2013, Pages 13-24

  Sitruk Ware, Regine ^a   Nath, Anita ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b POPULATION COUNCIL   (United States)

Author keywords

carbohydrate metabolism; coagulation factors; contraception; estrogen; lipids; progestin

Indexed keywords

19 NORPREGNANE DERIVATIVE; DIENOGEST; ELCOMETRINE; ESTETROL; ESTRADIOL; ESTRADIOL VALERATE; ESTRANE DERIVATIVE; ESTROGEN; ESTRONE SULFATE; ETHINYLESTRADIOL; GESTAGEN; GONANE DERIVATIVE; LIPID; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE; SPIRONOLACTONE; UNCLASSIFIED DRUG; VALERIC ACID;

ARTICLE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CONTRACEPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LIPID METABOLISM; LIVER METABOLISM; NONHUMAN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84873395410     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2012.09.004     Document Type: Review

References (75)

1. A. Chandra, G.M. Martinez, and W.D. Mosher Fertility, family planning, and reproductive health of U.S. women: data from the 2002 national survey of family growth Vital and health statistics series 23, data from the national survey of family growth vol. 25 2005 National Center for Health Statistics p. 1-160
2. J.J. Frost, and J.E. Darroch Factors associated with contraceptive choice and inconsistent method use, United States, 2004 Perspectives on Sexual and Reproductive Health 40 2008 94 104
3. M. Rad, C. Kluft, and J. Ménard Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables American Journal of Obstetrics and Gynecology 195 2006 72 77
4. S. Middeldorp, J.C. Meijers, and A.E. van den Ende Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study Thrombosis and Haemostasis 84 2000 4 8
5. G. Benagiano, C. Bastianelli, and M. Farris Hormonal contraception: present and future Drugs of Today 44 2008 905 923
6. D.J. Back, S. Madden, and M.L. Orme Gastrointestinal metabolism of contraceptive steroids American Journal of Obstetrics and Gynecology 163 1990 2138 2145
7. J.W. Goldzieher Pharmacokinetics and metabolism of ethinyl estrogens J.W. Goldzieher, K. Fotherby, Pharmacology of the contraceptive steroids 1994 Raven Press Ltd. New York 127 152
8. J.W. Goldzieher, G. Mileikowsky, and J. Newburger Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate Steroids 51 1988 63 79
9. K.A. Steingold, W. Cefalu, and W. Pardridge Enhanced hepatic extraction of estrogens used for replacement therapy The Journal of Clinical Endocrinology and Metabolism 62 1986 761 766
10. U. Goebelsmann, C.A. Mashchak, and D.R. Mishell Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol American Journal of Obstetrics and Gynecology 151 1985 868 877
11. C.A. Mashchak, R.A. Lobo, and R. Dozono-Takano Comparison of pharmacodynamic properties of various estrogen formulations American Journal of Obstetrics and Gynecology 144 1982 511 518
12. H. Kuhl Pharmacokinetics of oestrogens and progestogens Maturitas 12 1990 171 197
13. M.I. Cedars, and H.L. Judd Non oral routes of estrogen administration Obstetrics and Gynecology Clinics of North America 14 1987 269 298
14. A.B. Edelman, N.E. Carlson, and G. Cherala Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity Contraception 80 2009 119 127
15. J. Endrikat, H. Blode, and C. Gerlinger A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel The European Journal of Contraception & Reproductive Health Care 7 2002 79 90
16. R. Sitruk-Ware, G. Plu-Bureau, and J. Menard Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study The Journal of Clinical Endocrinology and Metabolism 92 2007 2074 2079
17. M.J. Wild, P.S. Rudland, and D.J. Back Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro The Journal of Steroid Biochemistry and Molecular Biology 45 1993 407 420
18. B. De Lignieres, A. Basdevant, and G. Thomas Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration The Journal of Clinical Endocrinology and Metabolism 62 1986 536 541
19. S. Palacios, L. Wildt, and S. Parke Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiolvalerate/dienogest): a phase III trial European Journal of Obstetrics, Gynecology and Reproductive Biology 149 2010 57 62
20. S. Zeun, M. Lu, and A. Uddin Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest The European Journal of Contraception & Reproductive Health Care 14 2009 221 232
21. C.J. Timmer, and T.B. Geurts Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study European Journal of Drug Metabolism and Pharmacokinetics 24 1999 47 53
22. B. Düsterberg, and Y. Nishino Pharmacokinetic and pharmacological features of oestradiol valerate Maturitas 4 1982 315 324
23. M. Visser, and H.J. Coelingh Bennink Clinical applications for estetrol The Journal of Steroid Biochemistry and Molecular Biology 114 2009 85 89
24. H.J. Coelingh Bennink, C.F. Holinka, and E. Diczfalusy Estetrol review: profile and potential clinical applications Climacteric 11 Suppl. 1 2008 47 58
25. H.J. Coelingh Bennink, S. Skouby, and P. Bouchard Ovulation inhibition by estetrol in an in vivo model Contraception 77 2008 186 190
26. R. Sitruk-Ware New progestagens for contraceptive use Human Reproduction Update 12 2006 169 178
27. Z. Liu, D. Auboeuf, and J. Wong Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486 Proceedings of the National Academy of Sciences of the United States of America 99 2002 7940 7944
28. H. Kuhl Comparative pharmacology of newer progestagens Drugs 51 1996 188 215
29. F.Z. Stanczyk Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception Reviews in Endocrine & Metabolic Disorders 3 2002 211 224
30. ®: a progestin with a unique pharmacological profile Steroids 65 2000 629 636
31. R. Sitruk-Ware, M. Small, and N. Kumar Nestorone: clinical applications for contraception and HRT Steroids 68 2003 907 913
32. M.C. Chu, X. Zhang, and E. Gentzschein Formation of ethinyl estradiol in women during treatment with norethindrone acetate The Journal of Clinical Endocrinology and Metabolism 9 2007 2205 2207
33. K. Chwalisz, E. Surrey, and F.Z. Stanczyk The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin- releasing hormone agonists in women with endometriosis Reproductive Science 19 2012 563 571
34. R.A. Edgren, and F.Z. Stanczyk Nomenclature of the gonaneprogestins Contraception 60 1999 313
35. A.E. Schindler, C. Campagnoli, and R. Druckmann Classification and pharmacology of progestins Maturitas 61 2008 171 180
36. M. Oettel, and C. Holz Hybrid progestins: the example of dienogest R. Sitruk-Ware, D.R. Mishell Jr. Progestins and antiprogestins in clinical practice 2000 M. Dekker New York 163 178
37. S. Sasagawa, Y. Shimizu, and H. Kami Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile Steroids 73 2008 222 231
38. H.D. McClamrock, and E.Y. Adashi Pharmacokinetics of desogestrel American Journal of Obstetrics and Gynecology 168 1993 1021 1028
39. A. Phillips, D.W. Hahn, and J.L. McGuire Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity American Journal of Obstetrics and Gynecology 167 1992 1191 1196
40. R. Sitruk-Ware, and A. Nath The use of newer progestins for contraception Contraception 82 2010 410 417
41. A.O. Mueck, and R. Sitruk-Ware Nomegestrol acetate, a novel progestogen for oral contraception Steroids 76 2011 531 539
42. E.M. Coutinho One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant) Contraception 47 1993 97 105
43. E. Ezan, H. Benech, and R. Bucourt Enzyme immunoassay for nomegestrol acetate in human plasma The Journal of Steroid Biochemistry and Molecular Biology 46 1993 507 514
44. R. Krattenmacher Drospirenone: pharmacology and pharmacokinetics of a unique progestogen Contraception 62 2000 29 38
45. I. Wiegratz, J.H. Lee, and E. Kutschera Effect of dienogest-containing oral contraceptives on lipid metabolism Contraception 65 2002 223 229
46. U.M. Ågren, M. Anttila, and K. Mäenpää-Liukko Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism The European Journal of Contraception & Reproductive Health Care 16 2011 444 457
47. U. Gaspard, J. Endrikat, and J. Desager A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles Contraception 69 2004 271 278
48. S. Taneepanichskul, and V. Phupong Influence of a new oral contraceptive with drospirenone on lipid metabolism Gynecological Endocrinology 23 2007 347 350
49. J.M. Manning, I.J. Edwards, and W.D. Wagner Effects of contraceptive estrogen and progestin on the atherogenic potential of plasma LDLs in cynomolgus monkeys Arteriosclerosis Thrombosis and Vascular Biology 17 1997 1216 1223
50. M.R. Adams, M.S. Anthony, and J.M. Manning Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys Obstetrics and Gynecology 96 2000 250 255
51. S. Parke, W. Junge, and U. Mellinger Oral comparative effects of a four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/ levonorgestrel on haemostatic parameters Human Reproduction 23 2008 i77
52. J. Jensen Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest Expert Opinion on Pharmacotherapy 11 2010 1147 1157
53. W. Junge, U. Mellinger, and S. Parke Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study Clinical Drug Investigation 31 2011 573 584
54. C. Kluft, J. Endrikat, and S.M. Mulder A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol Contraception 73 2006 336 343
55. U.H. Winkler, A.E. Schindler, and J. Endrikat A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol Contraception 53 1996 75 84
56. I. Wiegratz, J.H. Lee, and E. Kutschera Effect of four oral contraceptives on hemostatic parameters Contraception 70 2004 97 106
57. I. Wiegratz, S. Stahlberg, and T. Manthey Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters Contraception 78 2008 384 391
58. H.A. van Vliet, R.M. Bertina, and A.E. Dahm Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor Journal of Thrombosis and Haemostasis 6 2008 346 351
59. J. Conard, G. Plu-Bureau, and N. Bahi Progestogen-only contraception in women at high risk of venous thromboembolism Contraception 70 2004 437 441
60. L.A. Heinemann, A. Assmann, and T. DoMinh Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women The European Journal of Contraception and Reproductive Health Care 4 1999 67 73
61. A. Guilherme, J.V. Virbasius, and V. Puri Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes Nature Reviews Molecular Cell Biology 9 2008 367 377
62. F. Picard, M. Wanatabe, and K. Schoonjans Progesterone receptor knockout mice have an improved glucose homeostasis secondary to β-cell proliferation Proceedings of the National Academy of Sciences of the United States of America 99 2002 15644 15648
63. I.F. Godsland, C. Walton, and C. Felton Insulin resistance, secretion, and metabolism in users of oral contraceptives The Journal of Clinical Endocrinology and Metabolism 74 1992 64 70
64. V. Wynn, P.W. Adams, and I. Godsland Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism Lancet 1 1979 1045 1049
65. A. Basdevant, C. Pelissier, and J. Conard Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women Contraception 44 1991 599 605
66. T. Kojima, S.R. Lindheim, and D.M. Duffy Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives American Journal of Obstetrics and Gynecology 169 1993 1540 1544
67. I.F. Godsland, D. Crook, and R. Simpson The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism New England Journal of Medicine 323 1990 1375 1381
68. A. Cagnacci, S. Ferrari, and A. Tirelli Route of administration of contraceptives containing desogestrel/etonogestrel and insulin sensitivity: a prospective randomized study Contraception 80 2009 34 39
69. J.C. Dinger, L.A. Heinemann, and D. Kühl-Habich The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation Contraception 75 2007 344 354
70. J. Dinger, and S. Shapiro Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets The Journal of Family Planning and Reproductive Health Care 38 1 2012 2 6
71. S.S. Jick, and R.K. Hernandez Risk of nonfatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data British Medical Journal 342 2011 d2151
72. O. Lidegaard, L.H. Nielsen, and C.W. Skovlund Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and estrogen doses: Danish cohort study 2001-9 British Medical Journal 343 2011 d6423
73. O. Lidegaard, L.H. Nielsen, and C.W. Skovlund Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 British Medical Journal 344 2012 May 10 e2990 10.1136/bmj.e2990
74. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints (CHC-CVD final report 111022v2). http://www.fda.gov/downloads/ Drugs/DrugSafety/UCM277384.pdf.
75. J.A. Heit, C.E. Kobbervig, and A.H. James Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study Annals of Internal Medicine 143 2005 697 706